COVID-19 highlights the acute need for non-invasive, point-of-care, remote monitoring

hemodynamic measurement solutions. Find out how CPS meets the need.

Sensydia in the news

May 9, 2023

Sensydia raises $8M round

Non-invasive cardiac assessment company Sensydia today announced that it has raised approximately $8M in new funding from an expanded syndicate of investors. Proceeds of the financing will enable the company to prepare for commercialization of its groundbreaking non-invasive cardiac assessment platform, Cardiac Performance System (CPS™).

Learn More

Sensydia secures $3M NIH grant to advance AI-based cardiac assessment platform

Sensydia raises $8M round to advance breakthrough CPS cardiac assessment platform

Sensydia Achieves Study Target for Heart-Sound AI

Sensydia Receives FDA Breakthrough Device Designation for CPS Non-Invasive Cardiac Monitoring Device

Sensydia Appoints Anthony Arnold as President and Chief Executive Officer

FDA Clears Sensydia’s Cardiac Performance System